Does giving patients hospitalised with COVID-19 a synthetically made antibody that blocks the virus make them get better more quickly?

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19

What is this study about?

TICO is an international master protocol evaluating the safety and effectiveness of multiple new investigational agents, including neutralising antibodies that work by blocking SARS-CoV-2, the virus that causes COVID-19.

This master protocol is adaptive – which means it is flexible. Participants will be randomised to receive the new investigational agent(s) in addition to the current standard-of-care which includes the antiviral drug, remdesivir. TICO will enrol thousands of adults hospitalised with COVID-19. Any investigational agent(s) shown to be effective, will become the new ‘standard-of-care’ treatment, with far reaching global benefits.

Contact details


Who is funding the study?

National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)

When is it taking place?

July 2020 to December 2021

Where is it taking place?

France, Greece, Italy, Ireland, Switzerland, Uganda, UK and a number of other EU countries, USA, Central and South America, and SE Asia

Who is included?

Patients ≥18 years old admitted to hospital and diagnosed with SARS-CoV-2 infection